-+ 0.00%
-+ 0.00%
-+ 0.00%

Why Cettire, Gold Road, Imugene, and Paladin Energy shares are racing higher

The Motley Fool·01/03/2025 01:31:06
Listen to the news
A smiling businessman in the city looks at his phone and punches the air in celebration of good news.

The S&P/ASX 200 Index (ASX: XJO) is fighting hard to end the week on a positive note. In afternoon trade, the benchmark index is up 0.4% to 8,232.7 points.

Four ASX shares that are rising more than most today are listed below. Here's why they are climbing:

Cettire Ltd (ASX: CTT)

The Cettire share price is up 3.5% to $1.62. This is despite there being no news out of the online luxury products retailer. However, with its shares down over 40% since this time last year and 67% from their 52-week high, it seems that some investors believe that a buying opportunity has been created.

Gold Road Resources Ltd (ASX: GOR)

The Gold Road share price is up almost 3% to $2.12. This follows a decent night of trade for the gold price on Wall Street. According to CNBC, the gold futures price was up over 1% to US$2,668.8 an ounce during overnight trade on safe haven demand. This meant that the precious metal climbed to a two-week high. It isn't just Gold Road Resources that is rising today. The S&P/ASX All Ordinaries Gold index is up 2.5% at the time of writing.

Imugene Ltd (ASX: IMU)

The Imugene share price is up 2.5% to 4 cents. This morning, this immuno-oncology company released an update on its phase 1b clinical trial of its allogeneic CAR T-cell therapy azer-cel at the Royal Prince Alfred Hospital (RPAH) in Sydney. It is focused on patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), which is one of the most challenging and aggressive forms of non-Hodgkin's lymphoma. According to the release, the first Australian patient has been dosed in the Phase 1b clinical trial at the RPAH. Imugene CEO, Leslie Chong, said: "Achieving first patient dosed for azer-cel in Australia represents a significant milestone for Imugene and for Australian patients battling this devastating disease."

Paladin Energy Ltd (ASX: PDN)

The Paladin Energy share price is up 8% to $8.53. A number of ASX 200 uranium stocks are racing higher on Friday after industry giant Cameco announced the suspension of production at its joint venture with Kazatomprom. Cameco stated: "We are disappointed and surprised by this unexpected suspension and we will be seeking further clarification on how this transpired, as well as the potential 2025 and 2026 production and financial impacts (including on future dividends), and what Cameco can do to help Kazatomprom and JV Inkai restart mining operations."

The post Why Cettire, Gold Road, Imugene, and Paladin Energy shares are racing higher appeared first on The Motley Fool Australia.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2025